Marine lipid fraction PCSO-524 (lyprinol/omega XL) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma

Respir Med. 2013 Aug;107(8):1152-63. doi: 10.1016/j.rmed.2013.04.010. Epub 2013 May 7.

Abstract

Purpose: Evaluate the effect of the marine lipid fraction of the New Zealand green-lipped mussel (Perna canaliculus) PCSO-524 (Lyprinol/Omega XL), rich in omega-3 fatty acids, on airway inflammation and the bronchoconstrictor response to eucapnic voluntary hyperpnea (EVH) in asthmatics.

Methods: Twenty asthmatic subjects, with documented HIB, participated in a placebo controlled double-blind randomized crossover trial. Subjects entered the study on their usual diet and were then placed on 3 weeks of PCSO-524 or placebo supplementation, followed by a 2 week washout period, before crossing over to the alternative diet. Pre- and post-eucapnic voluntary hyperpnea (EVH) pulmonary function, fraction of exhaled nitric oxide (FENO), asthma symptom scores, medication use, exhaled breath condensate (EBC) pH, cysteinyl leukotrienes (cyst-LT), 8-isoprostane and urinary 9α, 11β-prostaglandin (PG)F2 and Clara (CC16) protein concentrations were assessed at the beginning of the trial and at the end of each treatment period.

Results: The PCSO-524 diet significantly reduced (p < 0.05) the maximum fall in post-EVH FEV1 (-8.4 ± 3.2%) compared to usual (-19.3 ± 5.4%) and placebo diet (-22.5 ± 13.7%). Pre- and post- EVH EBC cyst-LT and 8-isoprostane, and urinary 9α, 11β-PGF2 and CC16 concentrations were significantly reduced (p < 0.05) on the PCSO-524 diet compared to the usual and placebo diet. EBC pH and asthma symptom scores were significantly improved (p < 0.05) and rescue medication use significantly reduced (p < 0.05) on the PCSO-524 diet compared to the usual and placebo diet.

Conclusion: PCSO-524 (Lyprinol)/Omega XL) may have beneficial effects in HIB and asthma by serving as a pro-resolving agonist and/or inflammatory antagonist.

Keywords: Asthma; Diet; Inflammation; Omega-3 fatty acids.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / therapeutic use
  • Animals
  • Anti-Asthmatic Agents / administration & dosage*
  • Asthma / diet therapy
  • Asthma / physiopathology
  • Biological Products / administration & dosage*
  • Biomarkers / analysis
  • Bivalvia
  • Breath Tests
  • Bronchitis / diet therapy
  • Bronchitis / physiopathology
  • Bronchoconstriction / drug effects
  • Bronchodilator Agents / therapeutic use
  • Constriction, Pathologic / diet therapy
  • Cross-Over Studies
  • Dietary Supplements
  • Dinoprost / urine
  • Double-Blind Method
  • Fatty Acids, Omega-3 / administration & dosage
  • Female
  • Forced Expiratory Volume / physiology
  • Humans
  • Hyperventilation / physiopathology
  • Lipids / administration & dosage*
  • Male
  • Medication Adherence
  • Nitric Oxide / analysis
  • Uteroglobin / urine
  • Young Adult

Substances

  • Adrenergic beta-Agonists
  • Anti-Asthmatic Agents
  • Biological Products
  • Biomarkers
  • Bronchodilator Agents
  • Fatty Acids, Omega-3
  • Lipids
  • lyprinol
  • Nitric Oxide
  • Uteroglobin
  • Dinoprost